Silexion Therapeutics 成功完成 Sil204 的毒理学研究,为胰腺癌的 2/3 阶段临床试验做好准备

美股速递
Nov 25, 2025

Silexion Therapeutics 成功完成了 Sil204 的毒理学研究,这是一种下一代 RNA 静默疗法,为即将进行的胰腺癌 2/3 阶段临床试验做好了准备。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10